Evaluating Mucin-like Carcinoma Associated Antigen in Breast Cancer
Author Information
Author(s): E.H. Cooper, M.A. Forbes, A.K. Hancock, J.J. Price, D. Parker
Primary Institution: Unit for Cancer Research, University of Leeds
Hypothesis
Can mucin-like carcinoma associated antigen (MCA) levels serve as a reliable marker for breast cancer diagnosis and monitoring?
Conclusion
MCA levels can indicate metastatic disease in breast cancer patients, but caution is needed in interpreting isolated measurements.
Supporting Evidence
- 80% of patients with active metastatic disease had MCA levels greater than 15 U/ml.
- Rising MCA levels were observed in 12 out of 14 patients who developed metastases after surgery.
- Longitudinal studies showed stable MCA levels in patients who remained tumor-free for 5-9 years.
Takeaway
Doctors measured a special substance in the blood of women with breast cancer to see if it could help tell if the cancer was getting worse or coming back.
Methodology
Serum samples were collected from healthy women and breast cancer patients at various stages, and MCA levels were measured using a two-step enzyme-linked immunoassay.
Limitations
MCA levels overlap significantly with healthy controls, limiting its sensitivity for early detection.
Participant Demographics
Included 80 healthy women and 109 breast cancer patients, with a mix of premenopausal and post-menopausal participants.
Statistical Information
P-Value
0.017
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website